Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of VRC01.23LS, PGT121.414.LS, and PGDM1400LS in Adults Without HIV
NCT05959707Phase 1Suspended
- Sponsor
- HIV Vaccine Trials Network
- Start
- Aug 2024
- Primary completion
- Jan 2025
- Modality
- Anti-infectious Disease mAbs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of VRC01.23LS in human immunodeficiency virus infection (HIV) (8 arms), sponsored by HIV Vaccine Trials Network. Primary endpoints: Number of Local and systemic solicited AEs, unsolicited AEs, and SAEs at 6 months, Serum concentrations of VRC01.23LS, PGT121.414.LS, and PGDM1400LS at 8 months and 1 more. Started Aug 2024; status: suspended.
02
Drugs
VRC01.23LS
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05959707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05959707.